# OnCo record nsclc-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/nsclc-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "nsclc-signalling" ;
  schema:name "Non-small cell lung cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05223"@en, "Non-small cell lung cancer"@en ;
  schema:description "KEGG's non-small cell lung cancer map shows a set of alternative on-switches (EGFR mutation, KRAS mutation, EML4-ALK, RET and MET alterations) that all feed the same RAS/ERK, PI3K/AKT and STAT relays, plus loss of the p16 and p53 brakes. Each on-switch now has its own targeted pill, which is why molecular testing comes before treatment."@en ;
  schema:url <https://onco.cc/pathways/nsclc-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05223>, <https://doi.org/10.1038/nature25183> ;
  onco:related <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/sunvozertinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/brigatinib/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-herbst-nature/> .